Ironwood Pharmaceuticals (IRWD) Common Equity (2010 - 2026)
Ironwood Pharmaceuticals (IRWD) posted Common Equity of -$217.1 million for Q1 2026, up 17.07% sequentially from -$261.8 million in Q4 2025, and up 35.0% YoY from -$160.9 million in Q1 2025.
Ironwood Pharmaceuticals (IRWD) Common Equity (2010 - 2026) Analysis & Trends
Ironwood Pharmaceuticals has reported Common Equity for 17 years, with the latest figure at -$217.1 million in Q1 2026.
- Quarterly Common Equity rose 35.0% year-over-year to -$217.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$217.1 million (up 35.0% YoY) and the FY2025 annual result came in at -$261.8 million, up 13.11% from the prior year.
- Common Equity climbed to -$217.1 million in Q1 2026 per IRWD's latest filing, from -$261.8 million in the prior quarter.
- Over five years, Common Equity peaked at $1.4 billion in Q4 2023 and troughed at -$346.8 million in Q2 2023.
- A 5-year average of $60.8 million and a median of -$264.2 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity jumped 369.89% in 2022, then slumped 165.08% in 2023.
- Over 5 years, Common Equity stood at $652.4 million in 2022, then soared by 107.73% to $1.4 billion in 2023, then sank by 122.24% to -$301.3 million in 2024, then increased by 13.11% to -$261.8 million in 2025, then increased by 17.07% to -$217.1 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$217.1 million, -$261.8 million, and -$264.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 4.05 Bn |
| 10 | Ironwood Pharmaceuticals | 669.95 Mn | 590.82 Mn | - | -161.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -161.84 Mn |
| Mar 31, 2026 | -217.14 Mn |
| Dec 31, 2025 | -261.84 Mn |
| Sep 30, 2025 | -264.16 Mn |
| Jun 30, 2025 | -308.16 Mn |
| Mar 31, 2025 | -334.05 Mn |
| Dec 31, 2024 | -301.34 Mn |
| Sep 30, 2024 | -311.33 Mn |
| Jun 30, 2024 | -321.73 Mn |
| Mar 31, 2024 | -330.52 Mn |
| Dec 31, 2023 | 1.36 Bn |
| Sep 30, 2023 | -325.68 Mn |
| Jun 30, 2023 | -346.78 Mn |
| Mar 31, 2023 | 706.85 Mn |
| Dec 31, 2022 | 652.38 Mn |
| Sep 30, 2022 | 591.06 Mn |
| Jun 30, 2022 | 532.88 Mn |
| Mar 31, 2022 | 517.78 Mn |
| Dec 31, 2021 | 605.91 Mn |
| Sep 30, 2021 | 579.94 Mn |